Verapamil, a synthetic papaverine derivative, has been reported to have antiarrhythmic, antianginal, and antihypertensive properties in man (1). Although verapamil was introduced in Germany in 1962 and has been in use in much of the world, it has been available for clinical investigation in the United States only recently (1). The oral and intravenous use of verapamil is associated with side effects including gastric intolerance, headache, nervousness, pruritis, hypotension, bradycardia, and asystole (2); however, hyperprolactinemia and galactorrhea have not been reported. We report galactorrhea and hyperprolactinemia that occurred during verapamil therapy in a young woman.
A 22-year-old woman had a